| Similar Articles |
 |
Chemistry World August 1, 2014 Sarah Houlton |
Amgen to shed 2400-2900 jobs Most of the job losses will be in the US, predominantly at the former Immunex research facility in Seattle and two biologics manufacturing sites in Colorado.  |
Chemistry World March 13, 2015 Rebecca Trager |
Amgen to axe 300 Onyx employees US biotech Amgen plans to shutter the south San Francisco, US facility of Onyx Pharmaceuticals, the oncology specialist that it acquired in September 2013.  |
Chemistry World June 4, 2015 Phillip Broadwith |
Takeda to consolidate vaccines business in Boston Japanese pharma firm Takeda plans to close three US sites and move the headquarters of its vaccines business unit to the pharmaceutical hub in the Boston and Cambridge area of Massachusetts.  |
The Motley Fool July 12, 2004 Ben McClure |
Falling for Amgen Ahead of its second-quarter earnings release, the biotech giant looks good.  |
The Motley Fool July 21, 2005 Tom Taulli |
Amgen One-Ups Genentech New Medicare regulations look to be harmless, and as a result, Amgen is off to the races. Still, investing in biotech is always dicey.  |
The Motley Fool March 29, 2004 Jeff Hwang |
Amgen Deals Again Two years after acquiring Immunex, Amgen takes Tularik.  |
Chemistry World October 12, 2015 Rebecca Trager |
Monsanto plans 2600 layoffs The cuts, which will slash the company's workforce by about 12%, are part of a cost-saving plan to address declining sales of its biotech seeds and herbicides.  |
The Motley Fool March 15, 2007 Brian Lawler |
Amgen vs. Intel: Amgen In honor of the annual NCAA College Basketball Tournament, a.k.a. March Madness -- here is "Stock Madness 2007." Why Amgen deserves to win this match-up.  |
Chemistry World October 23, 2008 Matt Wilkinson |
Merck to slash more jobs Beleaguered US pharma giant, Merck & Co., has announced new restructuring plans that will see the company cut 7,200 jobs in an effort to save up to $4.2 billion  |
The Motley Fool October 24, 2006 Brian Lawler |
Amgen's Ho-Hum Quarter With all the money flowing into its coffers, the biotech has no excuse not to start paying a dividend.  |
The Motley Fool April 24, 2007 Brian Lawler |
Amgen On Sale? Biotech giant Amgen announces first-quarter financial results. Longer-term investors willing to wait for Amgen's drug pipeline to mature may be getting their chance to own a proven Ferrari at Ford prices.  |
The Motley Fool April 21, 2011 Luke Timmerman |
Amgen Passes Key Trial With "Son of Dmab" for Osteoporosis The medical and scientific world will be chirping today about an interesting new finding Amgen has made for treating osteoporosis.  |
BusinessWeek June 4, 2007 Gene G. Marcial |
Amgen Believers There has been a deluge of bad news at biotech Amgen, whose stock has tumbled.  |
Chemistry World January 20, 2012 Sarah Houlton |
Takeda slashes 10% of its workforce This represents about 10% of its workforce, and the cuts will be made in research, commercial and admin sections of the business.  |
The Motley Fool October 29, 2007 Brian Lawler |
Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader.  |
The Motley Fool November 8, 2011 Brian Orelli |
This Biotech Thinks It's Cheap Amgen thinks its investors aren't valuing the company properly. It's offering to repurchase $5 billion worth of stock -- about 10% of its value -- and even willing to borrow the cash to get it done.  |
The Motley Fool November 16, 2004 Charly Travers |
Finding Biotech's 50-Baggers Finding these superb biotechs isn't a search for a once-in-a-lifetime opportunity. These great investments pop up a lot more frequently than you may think.  |
The Motley Fool January 29, 2007 Brian Lawler |
No Amplified Growth for Amgen The drug developer recently released its fourth-quarter financial results. With a $71 share price and trading at roughly a forward multiple of 16 times earnings, the stock is not particularly cheap.  |
The Motley Fool December 16, 2003 Rick Aristotle Munarriz |
Amgen's Cannibalistic Ways Amgen's prospects look good, and it is planning a large share buyback.  |
The Motley Fool April 25, 2011 Brian Orelli |
Dividend Investors Rejoice! Or Not. Amgen establishes a dividend, investors yawn.  |
The Motley Fool October 25, 2011 Brian Orelli |
Anemic Growth in All the Right Places Amgen's anemia drugs decline, but that's not its future anyway.  |
The Motley Fool February 23, 2005 Brian Gorman |
Amgen Gets Disciplined Direct-to-consumer advertising may be a non-starter for Amgen and other biotech companies.  |
The Motley Fool October 7, 2004 Charly Travers |
Amgen's Next Blockbuster An osteoporosis drug could give the company its next big winner. With a P/E back in the mid 20s, the company is valued such that Amgen shareholders should be rewarded in the future if products are successful.  |
The Motley Fool December 26, 2006 Brian Lawler |
2006 in Review: Amgen For investors in shares of Amgen, it hasn't been a good year. The stock has been down more than 7% year to date. Despite this fact, Amgen has had successes on all fronts this year.  |
BusinessWeek May 15, 2006 Arlene Weintraub |
Rebuilding Amgen's Bones Amgen's mass-market osteoporosis drug could help reassure antsy investors.  |
Inc. May 1, 2002 Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies...  |
BusinessWeek March 22, 2004 Arlene Weintraub |
Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work?  |
BusinessWeek September 19, 2005 |
Biotech, Then and Now Amgen's George Rathmann explains how Big Pharma's role has evolved from detractor to investor, and why R&D needs more respect.  |
The Motley Fool May 27, 2009 Brian Orelli |
A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452.  |
Chemistry World October 14, 2013 Phillip Broadwith |
5000 jobs to be cut at Teva Israeli generics heavyweight Teva is accelerating its previously announced costcutting drive.  |
The Motley Fool April 28, 2008 Brian Lawler |
Amgen's Anemic Earnings Drug troubles and potential label changes continue to hurt Amgen's earnings.  |
Managed Care May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs.  |
IndustryWeek June 1, 2004 Tonya Vinas |
Amgen's Land Of Discovery Biotechnology behemoth Amgen Inc., based in Thousand Oaks, Calif., further capitalized on its acquisition of Immunex Corp. with the opening of a $625 million research and development campus in Seattle in February.  |
The Motley Fool October 31, 2011 Eric Bleeker |
Where Amgen Is Finding Its Growth Five years ago, Amgen collected 83% of its sales from the United States.  |
The Motley Fool March 28, 2008 Brian Orelli |
Wyeth Fires to Get Back on Fire The first round of Wyeth's cuts look like the right move for the big pharma company.  |
The Motley Fool June 28, 2004 Alyce Lomax |
Is Amgen's Engine Stalled? Amgen slipped in today's trading session after it said that an experimental drug for advanced cases of Parkinson's disease didn't meet its primary end point in a recent clinical trial.  |
The Motley Fool November 2, 2010 Jeremy Phillips |
Time to Sell Amgen? We're seeking danger signs among Fools' most beloved stocks.  |
The Motley Fool November 9, 2006 Karl Thiel |
The Best Blue Chip for 2007: Amgen Once a small biotech struggling to make its way in the world, Amgen has grown up. Investors, take note.  |
Bio-IT World July 14, 2004 |
Not Just a Day at the Beach Joseph Panetta recalls leaving the comfort of a pharma job in Philadelphia for a position in biotech in San Diego, whose fledgling biotech community survived stormy nascent years to mushroom into a biotech hotbed.  |
The Motley Fool December 20, 2011 Luke Timmerman |
Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs What does this important collaboration mean for biosimilars?  |
The Motley Fool June 7, 2007 Brian Lawler |
Acquisitive Amgen The biotech behemoth acquires Ilypsa and Alantos Pharmaceuticals. The all-cash deals for both companies gives Amgen several mid-stage drug candidates to beef up its drug pipeline.  |
The Motley Fool May 15, 2006 Brian Gorman |
AstraZeneca's Peer-Pressure Purchase The drug company seems to be paying a lot for Cambridge Antibody. Perhaps AstraZeneca didn't want to be left behind as its rivals bought up biotech technology -- but in its haste, it may be paying a steep price for what it's getting. Investors, take note.  |
Pharmaceutical Executive December 1, 2013 Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better.  |
IndustryWeek November 1, 2002 Tonya Vinas |
Questioning Biotech's Benefits While most communities are investing to attract or grow biotechnology companies, a recent report concludes that only a handful of cities will benefit in the long run.  |
The Motley Fool November 28, 2011 |
A Brief History of Amgen's Returns Amgen shares declined 17% over the past decade. What has happened?  |
The Motley Fool April 29, 2005 Charly Travers |
Value in Drug Stocks? Looking at some big pharma companies and liking what you see? Take a peek at biotech, too. GlaxoSmithKline... Pfizer... Amgen... Genzyme... etc.  |
Pharmaceutical Executive May 1, 2005 |
Thought Leaders: Playing Field in Biotech/Pharma Partnerships Levels As infrastructure and business savvy within biotechs become increasingly sophisticated, the sector's relationship with pharma is taking on a new shape. An interview with industry veteran Lisa Drakeman on how to integrate cultures and processes and where pharma is falling short.  |
Global Services May 28, 2008 Imrana Khan |
Number of Layoffs in the U.S. Touches a 19-Month High Interestingly, the ever-blamed outsourcing became the reason for only 3,576 job cuts in the country. Market conditions, business closing, cost cutting, restructuring, demand downturn and bankruptcy were the major reasons of job cuts in April 2008.  |
The Motley Fool July 30, 2007 Brian Lawler |
Amgen Adjusting Amgen's second quarter reflects the pain it's feeling with its top drugs. Investors, take note.  |
National Real Estate Investor June 1, 2003 H. Lee Murphy |
Who's Behind Biotech? There is a niche in the office market where vacancies are a fraction of the national rate, rents are way above average, and prospects for growth actually exist. It is the specialized (and regionally concentrated) business of supplying space to the biotech and life sciences industry.  |